Met Life Investment Management, LLC Cassava Sciences Inc Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 22,699 shares of SAVA stock, worth $62,422. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,699
Previous 22,699 -0.0%
Holding current value
$62,422
Previous $280,000 138.57%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$12.35 - $26.11 $28,120 - $59,452
2,277 Added 11.15%
22,699 $280,000
Q1 2024

May 14, 2024
BUY
$18.44 - $26.41 $376,581 - $539,345
20,422 New
20,422 $414,000
Q3 2023

May 09, 2024
BUY
$16.64 - $25.32 $11,365 - $17,293
683 Added 3.46%
20,422 $339,000
Q2 2023

Apr 29, 2024
BUY
$21.59 - $27.88 $440,910 - $569,365
20,422 New
20,422 $500,000
Q2 2023

Aug 10, 2023
BUY
$21.59 - $27.88 $14,745 - $19,042
683 Added 3.46%
20,422 $500,000
Q1 2023

May 09, 2024
BUY
$23.46 - $36.44 $463,076 - $719,289
19,739 New
19,739 $476 Million
Q4 2022

May 10, 2024
SELL
$27.82 - $44.16 $27,291 - $43,320
-981 Reduced 4.73%
19,739 $583,000
Q4 2022

Mar 22, 2023
SELL
$27.82 - $44.16 $27,291 - $43,320
-981 Reduced 4.73%
19,739 $583,000
Q4 2022

Feb 15, 2023
SELL
$27.82 - $44.16 $27,291 - $43,320
-981 Reduced 4.73%
19,739 $583,000
Q3 2022

Jun 14, 2023
BUY
$16.33 - $51.06 $16,019 - $50,089
981 Added 4.97%
20,720 $866,000
Q2 2022

May 10, 2024
SELL
$17.22 - $38.47 $18,804 - $42,009
-1,092 Reduced 5.01%
20,720 $582,000
Q2 2022

Jun 20, 2023
BUY
$17.22 - $38.47 $16,892 - $37,739
981 Added 4.97%
20,720 $582,000
Q2 2022

Mar 22, 2023
SELL
$17.22 - $38.47 $18,804 - $42,009
-1,092 Reduced 5.01%
20,720 $582,000
Q2 2022

Aug 11, 2022
SELL
$17.22 - $38.47 $18,804 - $42,009
-1,092 Reduced 5.01%
20,720 $583,000
Q1 2022

May 10, 2024
BUY
$32.6 - $53.05 $711,071 - $1.16 Million
21,812 New
21,812 $810,000
Q1 2022

Jun 20, 2023
BUY
$32.6 - $53.05 $67,579 - $109,972
2,073 Added 10.5%
21,812 $810,000
Q1 2022

Mar 22, 2023
BUY
$32.6 - $53.05 $262,430 - $427,052
8,050 Added 58.49%
21,812 $810,000
Q1 2022

May 12, 2022
BUY
$32.6 - $53.05 $262,430 - $427,052
8,050 Added 58.49%
21,812 $810,000
Q4 2021

Jun 21, 2023
SELL
$36.77 - $90.91 $219,774 - $543,369
-5,977 Reduced 30.28%
13,762 $601,000
Q3 2021

Jun 21, 2023
SELL
$41.79 - $135.3 $249,778 - $808,688
-5,977 Reduced 30.28%
13,762 $854,000
Q2 2021

May 17, 2024
BUY
$32.15 - $89.72 $34,947 - $97,525
1,087 Added 8.58%
13,762 $1.18 Million
Q2 2021

Jun 21, 2023
SELL
$32.15 - $89.72 $192,160 - $536,256
-5,977 Reduced 30.28%
13,762 $1.18 Million
Q2 2021

Mar 22, 2023
BUY
$32.15 - $89.72 $34,947 - $97,525
1,087 Added 8.58%
13,762 $1.18 Million
Q2 2021

Aug 16, 2021
BUY
$32.15 - $89.72 $34,947 - $97,525
1,087 Added 8.58%
13,762 $1.18 Million
Q1 2021

May 17, 2024
SELL
$7.09 - $87.95 $54,926 - $681,348
-7,747 Reduced 37.93%
12,675 $569,000
Q1 2021

Jun 26, 2023
SELL
$7.09 - $87.95 $50,083 - $621,278
-7,064 Reduced 35.79%
12,675 $570 Million
Q1 2021

Mar 22, 2023
SELL
$7.09 - $87.95 $22,836 - $283,286
-3,221 Reduced 20.26%
12,675 $569,000
Q1 2021

May 14, 2021
SELL
$7.09 - $87.95 $22,836 - $283,286
-3,221 Reduced 20.26%
12,675 $570,000
Q4 2020

May 24, 2024
SELL
$6.79 - $12.25 $30,731 - $55,443
-4,526 Reduced 22.16%
15,896 $108,000
Q4 2020

Jun 22, 2023
SELL
$6.79 - $12.25 $26,093 - $47,076
-3,843 Reduced 19.47%
15,896 $108,000
Q4 2020

Mar 22, 2023
SELL
$6.79 - $12.25 $26,093 - $47,076
-3,843 Reduced 19.47%
15,896 $108,000
Q4 2020

Feb 16, 2021
BUY
$6.79 - $12.25 $107,933 - $194,726
15,896 New
15,896 $108,000

Others Institutions Holding SAVA

# of Institutions
201
Shares Held
13.9M
Call Options Held
2.98M
Put Options Held
6.57M
View Full List

About CASSAVA SCIENCES INC

SAVA Quotes by TradingView
  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $110M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email